Literature DB >> 10812273

Trichosporon beigelii infection: experience in a regional burn center.

M J Cawley1, G R Braxton, L R Haith, K J Reilly, R E Guilday, M L Patton.   

Abstract

Trichosporon beigelii is a fungus once thought to cause only superficial infections, but recently has been increasingly identified as an opportunistic systemic pathogen in immunocompromised patients. There have been very limited reports of this organism in the burn patient population. We describe the first report of pharmacological management of invasive T. beigelii with a combination of amphotericin B and high dose fluconazole in a burn patient. Antifungal susceptibility testing of T. beigelii determined a change in minimum inhibitory concentrations (MICs) of amphotericin B and a consistent resistance pattern with the use of flucytosine. This paper will review our experience with T. beigelii fungus in a regional burn treatment center and review the literature on other experiences in the burn population.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10812273     DOI: 10.1016/s0305-4179(99)00181-3

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  19 in total

1.  In vitro antifungal susceptibilities of Trichosporon species.

Authors:  Niki I Paphitou; Luis Ostrosky-Zeichner; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

2.  Clinical case of endocarditis due to Trichosporon inkin and antifungal susceptibility profile of the organism.

Authors:  Jose M Ramos; Manuel Cuenca-Estrella; Felix Gutierrez; Matilde Elia; Juan L Rodriguez-Tudela
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

3.  In vitro antifungal susceptibilities of uncommon basidiomycetous yeasts.

Authors:  Carolina Serena; Francisco Javier Pastor; Montserrat Ortoneda; Javier Capilla; Nicole Nolard; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

4.  Disseminated trichosporonosis in a burn patient: meningitis and cerebral abscess due to Trichosporon asahii.

Authors:  Orville D Heslop; May-Phyo Nyi Nyi; Sean P Abbott; Lois E Rainford; Daphney M Castle; Kathleen C M Coard
Journal:  J Clin Microbiol       Date:  2011-10-19       Impact factor: 5.948

5.  [Not Available].

Authors:  Jf Arnould; R Le Floch
Journal:  Ann Burns Fire Disasters       Date:  2015-03-31

6.  Microbiological characteristics of medically important Trichosporon species.

Authors:  Hou-Min Li; Hong-Tao Du; Wei Liu; Zhe Wan; Ruo-Yu Li
Journal:  Mycopathologia       Date:  2005-10       Impact factor: 2.574

7.  Efficacy of voriconazole in a guinea pig model of invasive trichosporonosis.

Authors:  Carolina Serena; Félix Gilgado; Marçal Mariné; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 8.  Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature.

Authors:  Corrado Girmenia; Livio Pagano; Bruno Martino; Domenico D'Antonio; Rosa Fanci; Giorgina Specchia; Lorella Melillo; Massimo Buelli; Giampaolo Pizzarelli; Mario Venditti; Pietro Martino
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

9.  Susceptibility patterns and molecular identification of Trichosporon species.

Authors:  Juan L Rodriguez-Tudela; Teresa M Diaz-Guerra; Emilia Mellado; Virginia Cano; Cecilia Tapia; Alexander Perkins; Alicia Gomez-Lopez; Laura Rodero; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

10.  Efficacy of micafungin in combination with other drugs in a murine model of disseminated trichosporonosis.

Authors:  Carolina Serena; F Javier Pastor; Félix Gilgado; Emilio Mayayo; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.